Intelligence · Clinical pipeline
Oncology R&D Pipeline
Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.
Quick answer
Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.
Top sponsors
- First People's Hospital 474 programs
- Chinese Academy of 400 programs
- United Therapeutics Europe 219 programs
- George Institute for 172 programs
- Takeda 163 programs
- HOFFMANN-LA ROCHE 144 programs
- AstraZeneca 143 programs
- MSD Merck Sharp 131 programs
- Regeneron UK 128 programs
- Anaxis Pharma 125 programs
- Telethon Foundation 113 programs
- Novartis India 110 programs
Pipeline programs
-
APVO436
Aptevo Therapeutics
Acute Myeloid Leukemia (AML)
1 trial -
ARC-12
Arcus Biosciences
Multiple Myeloma, Diffuse large B cell lymphoma (DLBCL), Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Melanoma, Advanced Solid Tumor, Gastrointestinal (GI) cancer, Hematological (heme) cancer, Gynecological (Gyn) cancer, Non-small cell lung cancer (NSCLC), Non-Hodgkin Lymphoma, Gastric Cancer, Cervical Cancer
1 trial -
ARC-20
Arcus Biosciences
Solid Tumors, Clear Cell Renal Cell Carcinoma
1 trial -
ARISE with AR
BRIGHT MINDS BIOSCIENCES INC.
Pediatric Cancer
1 trial -
ARO-HIF2
Arrowhead Pharmaceuticals Ireland Limited
Clear Cell Renal Cell Carcinoma
1 trial -
ARQ 197
KYOWA KIRIN AUSTRALIA PTY LTD
Advanced Hepatocellular Carcinoma
1 trial -
ASTX660
United Therapeutics Europe Ltd
Advanced Cancer
1 trial -
ASTX727-17
Taiho Pharma Netherlands B.V.
Acute myeloid lymphoma (AML), myelodysplastic syndrome (MDS), or solid tumors
1 trial -
ASTX727-18
Taiho Pharma Netherlands B.V.
Solid tumor, Acute myeloid lymphoma (AML), Myelodysplastic syndrome (MDS)
1 trial -
ATA3219
Evidence Based Cataract Study Group
Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
1 trial -
ATG-010 and ATG-008
Shanghai Antengene Corporation Limited
Relapsed/Refractory Diffuse Large B-cell Lymphoma
1 trial -
ATI-2231
Aclaris Therapeutics
Advanced Solid Tumor
1 trial -
ATRA
United Therapeutics Europe Ltd
Pancreatic Adenocarcinoma
1 trial -
AU-011
Aura Biosciences
Non-muscle-invasive Bladder Cancer
1 trial -
AVE0005 (aflibercept)
Regeneron UK Limited
Colorectal Neoplasms
1 trial -
AVI-4126 Injection (RESTEN-NG®)
Sarepta Therapeutics
Neoplasms
1 trial -
AVN-944 capsules for oral administration
Vertex Pharmaceuticals (Australia) Pty.
Acute Leukemia
1 trial -
AZD0530
AstraZeneca
Solid Tumor
1 trial -
AZD2014 3 on/4 off & weekly paclitaxel
United Therapeutics Europe Ltd
Advanced Cancer
1 trial -
AZD3514
AstraZeneca
Prostate Cancer
1 trial -
AZD5363+Olaparib+Durvalumab
Hospital Authority, Hong Kong
Solid Tumor, Adult
1 trial -
AZD6244
AstraZeneca
Neoplasms,
1 trial -
AZD7762
AstraZeneca
Cancer
1 trial -
AZD9150
IONIS PHARMACEUTICALS INC
Advanced Adult Hepatocellular Carcinoma
1 trial -
AdV-tk
Candel Therapeutics
Pancreatic Adenocarcinoma
1 trial -
Adoptive Cell Therapy with Tumor-infiltrating Lymphocytes (TIL)
United Therapeutics Europe Ltd
Urothelial Carcinoma
1 trial -
Aflibercept (AVE0005)
Regeneron UK Limited
Neoplasm Malignant
2 trials -
Alisertib
Takeda
Solid Tumors
1 trial -
Alisertib
Takeda
B-cell Follicular Lymphoma
1 trial -
Alisertib
Takeda
Advanced Solid Tumors
7 trials -
All-trans retinoic acid
The First People's Hospital of Lianyungang
Acute Myeloid Leukemia
1 trial -
Allogeneic anti-CD7 CAR-T cells (BEAM-201)
Beam Therapeutics
T-Cell Acute Lymphoblastic Leukemia/Lymphoma
1 trial -
An Open-Label for Solid tumors and ovarian cancer
Lacuna Pharma Pty Ltd
Solid tumors and ovarian cancer
1 trial -
An Ophthalmic Safety Study of New Investigational Drug in Breast Cancer Patients
AstraZeneca AB
Breast Cancer
1 trial -
An open label for High grade serous ovarian cancer
Disc Medicine
High grade serous ovarian cancer
1 trial -
Anlotinib hydrochloride,Penpulimab
The First People's Hospital of Lianyungang
Colorectal Cancer
1 trial -
Anti-CD123 CAR NK cells
Chongqing Precision Biotech Co., Ltd
AML (Acute Myeloid Leukemia)
1 trial -
Anti-CD19 Universal CAR-T Cells injection
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
1 trial -
Anti-CD19-CAR
The First People's Hospital of Lianyungang
Leukemia
1 trial -
Anti-CD30 CAR T cells
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Adult T-Cell Lymphoma/Leukaemia
1 trial -
Anti-CD5 CAR NK cells
Chongqing Precision Biotech Co., Ltd
T-ALL/Lymphoma
1 trial -
Anti-CDH17 CAR-T cells infusion
Xiyuan Hospital of China Academy of Chinese Medical Sciences
CDH17-positive Advanced Solid Tumors
1 trial -
Anti-CLL1 CART cells
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Acute Myeloid Leukemia
1 trial -
Anti-GD2 ADC M3554 in Advanced Solid Tumors
Merck Sharp and Dohme
Advanced Solid Tumors
1 trial -
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
Merck Sharp and Dohme
Advanced Solid Tumors
1 trial -
Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody
Takeda
Metastatic Adenocarcinoma of the Colon or Rectum
1 trial -
Anti-SEMA4D Monoclonal Antibody VX15/2503
VACCINEX, INC.
Colon Carcinoma Metastatic in the Liver
1 trial -
Anti-SEMA4D Monoclonal Antibody VX15/2503
VACCINEX, INC.
Metastatic Melanoma
1 trial
Frequently asked questions
How many oncology pipeline programs are tracked?
5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.
Where does pipeline data come from?
ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.